Pharmapark Will Market Prestige's Trastuzumab In Russia
Prestige BioPharma has struck a deal with Pharmapark to market Prestige’s trastuzumab biosimilar in the Russian Federation.
You may also be interested in...
Alvotech and Prestige Biopharma have announced a new contract manufacturing partnership for one of Prestige’s biosimilar candidates.
Mundipharma has struck a deal with Prestige BioPharma for rights to the Singapore-based firm’s biosimilar trastuzumab in selected European markets.
Products Roundup - 19 December 2018: European Commission Approves Mylan/Biocon’s Ogivri Biosimilar, Amgen Files Infliximab With The FDA And Hikma Debuts Dalfampridine
The latest generic, biosimilar and value-added drug development news and highlights from across the globe.